Tuberous sclerosis is an autosomal dominant trait in which the dysregulation of cellular proliferation and differentiation results in the development of hamartomatous growths in many organs. The TSC2 gene is one of two genes determining tuberous sclerosis. Inactivating germline mutations of TSC2 in patients with tuberous sclerosis and somatic loss of heterozygosity at the TSC2 locus in the associated hamartomas indicate that TSC2 functions as a tumour suppressor gene and that loss of function is critical to expression of the tuberous sclerosis phenotype. The TSC2 product, tuberin, has a region of homology with the GTPase activating protein rap1GAP and stimulates the GTPase activity of rap1a and rab5a in vitro. Here we show that the region of homology between tuberin and human rap1GAP and the murine GAP mSpa1 is more extensive than previously reported and spans ∼160 amino acid residues encoded within exons 34-38 of the TSC2 gene. Single strand conformation polymorphism analysis of these exons in 173 unrelated patients with tuberous sclerosis and direct sequencing of variant conformers together with study of additional family members enabled characterisation of disease associated mutations in 14 cases. Missense mutations, which occurred in exons 36, 37 and 38 were identified in eight cases, four of whom shared the same recurrent change P1675L. Each of the five different missense mutations identified was shown to occur de novo in at least one sporadic case of tuberous sclerosis. The high proportion of missense mutations detected in the region of the TSC2 gene encoding the GAP-related domain supports its key role in the regulation of cellular growth.
INTRODUCTION
Tuberous sclerosis (TSC) is an autosomal dominant multisystem disorder with a birth frequency in excess of 1 in 10 000. It is characterised by the development of a spectrum of hamartomas (tumour like growths) of the brain, skin, kidneys, heart and other organs. The unpredictable distribution of hamartomas results in a wide variety of signs, symptoms and complications (1) . Linkage studies have demonstrated locus heterogeneity in TSC; roughly equal proportions of multigeneration families show linkage to 9q34 and 16p13.3 (2) . At least 60% of cases are sporadic and appear to represent new mutations (3) , although the proportions of sporadic cases with mutation of TSC1 and TSC2 has not yet been determined. The TSC2 gene on 16p13.3 has been identified by positional cloning (4) . It spans ∼43 kb of genomic DNA and encodes a number of alternatively spliced transcripts of ∼6 kb. Constitutional inactivating mutations of the TSC2 gene, including complete deletion, have been detected in patients with tuberous sclerosis (4, 5) and the associated hamartomas show loss of heterozygosity for markers in the TSC2 region (6) (7) (8) , indicating that TSC2 functions as a tumour suppressor gene and that loss of function of both alleles is normally required before cellular growth becomes dysregulated.
The cellular roles of the TSC2 product, tuberin have not yet been determined. However, tuberin has a region of homology with the GTPase activating protein rap1GAP (4) , which down-regulates the activity of the ras-related proteins rap1a and rap1b (9) . The GAP-related domain of tuberin is highly conserved in mouse (10) , rat (11) and pufferfish (12) . Both native tuberin and bacterially expressed C-terminal fragments of the protein which include the GAP-related domain stimulate the intrinsic GTPase activity of both rap1 and rab5a in vitro (13, 14) . Thus, tuberin may function as a GTPase activating protein, though the physiological target for this activity remains unclear. This possibility is intriguing since neurofibromin, the product of the NF1 tumour suppressor gene, acts as a GAP for p21ras and NF1 is mutated in another multisystem hamartomatosis, neurofibromatosis type 1 (15) .
Analysis of mutations of the TSC2 gene may provide insight into the functional domains of tuberin, and may provide a valuable resource for further investigation of the putative functions of tuberin. To facilitate the identification of subtle mutations of TSC2 we have previously determined the genomic structure of the gene in man. Forty one coding exons and one leader exon were identified (12, 16) . Here we show that homology between tuberin and rap1GAP extends over a region of ∼160 *To whom correspondence should be addressed. Tel: +44 1222 744050; Fax: +44 1222 747603; Email: wmgjrs@cardiff.ac.uk Figure 1 . Alignment of the predicted amino acid sequences encoded by exons 34-38 of tuberin (hTSC2: L48546) and the rat homologue (rTSC2: U24150); human rap1GAP (M64788) and the mouse protein Spa1 (D11374 and Minato et al. in preparation). The amino acid residues are numbered at the right side and the exon numbers and intron/exon boundaries of the TSC2 sequence are indicated above. The missense mutations characterised in this study are shown with the site asterisked and the substituted residue indicated above. amino acid residues encoded by exons 34-38 of the TSC2 gene. We have studied these exons for mutations in 173 unrelated patients with tuberous sclerosis using single strand conformation polymorphism analysis and direct sequencing of abnormal conformers. Characterisation of the variant alleles, together with analysis of samples from additional family members, identified likely disease causing mutations in 14/173 unrelated patients of whom eight had missense mutations. Six neutral polymorphisms were also identified. The proportion of missense mutations observed supports the functional importance of tuberin's GAPrelated domain and the mutants themselves provide a resource for further investigation of tuberin's putative GAP activity.
RESULTS

Homology between tuberin and rap1GAP
In an earlier study (4), we reported that a region of 58 amino acids near the C-terminus of tuberin was homologous to part of the rap1GAP catalytic domain, fulfilling the criteria for structural identity defined by Sander and Schneider. Analysis of tuberin, rap1GAP and the murine GAP, Spa1, using the FASTA (17) program showed that the homology between tuberin and the GAPs is more extensive (Fig. 1) . Of the 157 amino acid residues between 1517 and 1674 of human tuberin, 32.5% are identical and 63.1% identical or similar to those of human rap1GAP. This region of tuberin is encoded within exons 34-38 of the TSC2 gene.
Identification and characterisation of mutations
Primer sets were designed to amplify each of exons 34-38, including their splice site boundaries (Table 1) . Single strand conformation polymorphism analysis of the amplified products identified variant conformers in 24 of 173 samples (Fig. 2 ). These were directly sequenced. Potentially disease causing mutations were identified in 15 samples. Nucleotide changes which did not alter the encoded amino acid were identified in 10 samples (one sample yielding both a neutral nucleotide change and a probable disease causing mutation). The neutral changes were a polymorphism observed in four cases (4977 C→T) and six unique variants (4554 C→T, 4680+41 G→C, 4680+17 G→A, 4680+18 G→A, 4707 C→T and 4929 G→A). The families of the 15 patients in whom possible disease causing mutations had been identified were further studied in order to assess the evidence for pathogenicity of the lesions.
Missense changes which were likely to be pathogenic were characterised in eight unrelated patients ( Table 2 ). The substitution P1675L resulting from a C→T transition at the CpG dinucleotide 5042-5043 was observed in four unrelated patients, three apparently sporadic cases and one who had inherited TSC from her deceased father. The clinically normal parents of one sporadic case were available for analysis. De novo occurrence of the mutation was confirmed in the affected patient and genotypes at five highly polymorphic microsatellite loci were consistent with biological paternity and maternity. These observations and the non-conservative nature of the substitution indicated that the mutation was pathogenic. The base change abolishes an AciI site which was found to be present in all of 124 control chromosomes tested. 
Four unique missense changes were also characterised. The substitution N1651S was identified in a two generation family with tuberous sclerosis (Fig. 3) . Analysis of samples from the clinically normal parents of the proband confirmed that the causative A→G transition at nucleotide 4970 had occurred de novo and genotypes at five polymorphic microsatellite loci were found to be consistent with biological parenthood. The mutant allele was transmitted to the two affected sons of the proband, but not to his clinically unaffected son. The mutation alters a potential N-linked glycosylation site.
The non-conservative substitution N1643K resulting from a C→G transition at the CpG dinucleotide 4947-4948 was observed in one apparently sporadic case of tuberous sclerosis in whom a neutral C→T transition at nucleotide 4977 (S1653) was also detected. N1643 is conserved between the GAP domains of tuberin, rap1GAP and murine Spa1 (Fig. 1) . The mutation creates an EcoNI restriction site which was assayed and found to be absent in the patient's clinically normal mother and three siblings. Her apparently normal father was dead and, in order to assess whether the mutation had occurred de novo in the patient, the living relatives were genotyped for the intragenic polymorphism at nt 4977 and the polymorphic markers GGG1, KG8, SM6 and AC2.5 which flank and are tightly linked to the TSC2 locus (4). Haplotype analysis indicated that the mutation had occurred de novo, although it was not possible to determine whether the mutation had arisen in the paternal or maternal germline or as a post-zygotic somatic mutation (Fig. 4) .
Two further missense mutations, N1682K and L1594M, were each shown to occur de novo in single sporadic cases. Again microsatellite analysis was consistent with biological paternity and maternity. Although the first of these substitutions changes a non-charged residue for a positively charged residue, the second is a relatively conservative change and the reason for its apparent pathogenicity is unclear.
Non-missense mutations were identified and characterised in six cases (Table 2) . Two were nonsense mutations, G1665X and Y1571X. Both were in apparently sporadic cases. De novo occurrence was demonstrated in the former but the parents of the second case were not available for analysis. Four frameshift mutations were identified, 4512 ins C, 4559 del 4 bp, 4594 del 7 bp and 4609 del G. These were predicted to generate novel stop codons 72, 183, 148 and 133 bp downstream, respectively. All were in apparently sporadic cases.
In a further sporadic case an in-frame deletion of a single codon, ∆F 1509, was observed. Analysis of samples from the parents who had no clinical evidence of TSC showed that the variant allele had been inherited from the patient's father. We also observed the same variant allele in five non-affected members of a further TSC family, strongly suggesting that the change represents a rare non-pathogenic variant. 
Associated phenotypes
Four unrelated patients shared the missense mutation P1675L. They had disease manifestations of markedly different severity. Two had epilepsy, were severely mentally retarded and had multiple skin stigmata of TSC. Neither had been investigated for evidence of renal involvement. The third had epilepsy and moderate mental retardation, typical skin signs and severe renal involvement with angiomyolipomas. The fourth (patient 5241 who had inherited TSC from her mildly affected father) was seizure free and mentally normal with only minor cosmetic problems due to skin involvement. She had not had renal investigation. Although numbers were small, there was no clear difference in the symptomatic severity of central nervous system disease between patients with missense and truncating mutations. Of 10 patients with missense mutations (including three in the same family) nine had epilepsy and seven were mentally retarded. Of six cases with truncating mutations five had epilepsy and four were mentally retarded. None of the patients with mutations in the GAP-related domain had recognised renal cystic disease or pulmonary involvement.
DISCUSSION
Loss of heterozygosity in a wide variety of TSC-associated hamartomas and carcinomas indicates that TSC2 acts as a tumour or growth suppressor gene, playing a regulatory role in the growth and proliferation of many cell types (6) (7) (8) . The missense mutations identified in this study implicate the GAP-related domain of tuberin as a key mediator of this major function of tuberin. The residues involved in these missense mutations may be critical to the interaction between the GAP domain and its physiological target. However, it is of interest that three of the four residues are not conserved between tuberin and rap1GAP and this may reflect functional differences between these domains. Further insights into the mechanisms of tumourigenesis in TSC may be gained by investigating the effects of the missense changes we have identified on the stability, sub-cellular localisation and GAP activity of tuberin.
To date, ∼60 mutations of the TSC2 gene have been reported in man (4, 5, (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) . Many of these have been large deletions. In part this reflects the methodologies employed for mutation detection and, in approximately half of the reported cases, selection of patients with the phenotype of TSC and polycystic kidneys, most of whom have contiguous deletions of TSC2 and PKD1 (5, 25) . Most of the other reported mutations have been truncating and the true frequency of missense mutations in the TSC2 gene as a whole is not known. Five putative TSC2 missense mutations have been described previously, all outside the GAP related domain (22) . The positions of two of these were originally mis-reported as being in exon 37 (patients TSC-115 and TSC117; ref. 27 ) but affect residues encoded in exon 39. Furthermore, the pathogenicity of these and of two of three other previously reported missense mutations remains uncertain, as de novo occurrence with appearance of the TSC phenotype was not demonstrated (22) . Similarly, the in-frame deletion ∆F 1509 (which lies just outside the region of GAP homology predicted by FASTA) has been reported as a disease causing mutation (22) , but we have now demonstrated that this change is likely to be a rare non-pathogenic polymorphism. In the present study we were careful to both document de novo occurrence of each of the missense mutations we identified and to establish evidence supporting biological parenthood of the patients involved. The dangers of misinterpreting the pathogenicity of sequence variation will be particularly relevant as genetic testing (including pre-natal testing) for TSC is introduced.
TSC2 has a complex structure, with 41 exons and a leader exon (12, 16) and diagnostic analysis of the gene represents a considerable challenge. The protein truncation test (PTT) is a promising approach to the identification of truncating mutations in complex genes and has been employed at the TSC2 locus (23, 24) . However, missense changes are not detected by PTT and our data suggest that this will limit its sensitivity at the TSC2 locus. We identified the same missense mutation (P1675L) in four of the eight unrelated patients with missense mutations exons 34-38. This mutation could be specifically assayed in the diagnostic setting. It is not yet known whether other recurrent mutations will be found to account for a significant proportion of all TSC2 mutations.
The demonstration of missense, nonsense and frameshift mutations in the exons we have investigated confirms the broad spectrum of mutations which can be associated with TSC. The only correlation between genotype and phenotype which has so far been established at the TSC2 locus is an association between large contiguous deletions of TSC2 and the adjacent PKD1 gene and polycystic kidneys in patients with tuberous sclerosis (5, 25) . In the present study the prevalence of epilepsy and mental retardation (two relatively easily quantified aspects of the TSC phenotype) were similar in patients with missense mutations and in patients with truncating mutations. Considerable variation in disease severity is apparent between different affected members of families with TSC (28), perhaps because of the importance of somatic 'second-hit' mutations in determining many aspects of the TSC phenotype. Nonetheless, correlations between genotype and phenotype are seen in disorders associated with 'two hit' inactivation of tumour suppressor genes. For example, in Von Hippel-Lindau disease missense mutations are associated with a high risk of phaeochromocytoma, a tumour which is rarely seen in patients with inactivating germline mutations of the VHL gene (29) . Further studies of genotype and phenotype are required in TSC. However, the pleiotropic expression of the disorder, the complex structure of the TSC2 locus and the existence of a second locus, TSC1, are likely to make these studies difficult.
MATERIALS AND METHODS
Patients
One hundred and seventy three unrelated patients with TSC were sequentially ascertained at the Institute of Medical Genetics, Cardiff, as part of ongoing studies into clinical and genetic aspects of the condition. We had also actively ascertained patients with the phenotype of tuberous sclerosis and polycystic kidney disease for a seperate study and these were excluded from the present series. All fulfilled the diagnostic criteria recommended by the Diagnostic Criteria Committee of the National Tuberous Sclerosis Association (30) .
PCR
Amplification of genomic DNA was carried out in a total volume of 50 µl containing 0.2 mM dNTPS, 25 pmol of each primer, 4% DMSO, 1 U Cetus Taq polymerase and 5 µl PCR buffer (10 mM Tris-HCl, 50 mM KCl, 2 mM MgCl 2 ). PCR conditions for each primer set were 95_C for 2 min followed by 30-33 cycles of 95_C for 1 min, 58-66_C for 1 min, 72_C for 2 min.
SSCP analysis and DNA sequencing
Following PCR amplification, products were diluted 1:10 with gel loading buffer (95% formamide, 20 mM EDTA, 0.05% bromophenol blue, 0.05% xylene cyanol) heated to 95_C for 2 min, cooled immediately on ice prior to loading, and applied to a 0.6× MDE gel. Products in the range of 200-260 bp were run at 9W for 8 h, while the 380 bp product was run at 5W for 16 h. Gels were blotted for 5-16 h and then hybridised with 1 µl of [α-32 P]labelled normal PCR product. Direct sequencing was by either PCR product sequencing kit (Amersham), or the Thermosequenase cycle sequencing kit (Amersham), used according to manufacturers' specifications. Sequencing reactions were electrophoresed on a 6% sequencing gel. For each of the de novo mutations identified, biological paternity and maternity were assessed using microsatellite markers on chromosomes 4 (D4S43), 6 (D6S250), 7 (D7S636), 15 (D15S945) and 16 (D16S665).
